Correlation Between Sunitinib Exposure and Toxicity in a Real-life Patient Cohort - Kim Westerdijk

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2019

Drug - Food Interaction an Unrealized Potential - Nielka van Erp, PharmD, PhD

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2019

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019

Oxazolidinones for TB: Current Status and Future Prospects - Lawrence Geiter

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019

Evaluating Hepatotoxicity of Bedaquiline Treatment in Multi-Drug Resistant Tuberculosis Patients - Lénaïg Tanneau

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019

Relationship Between Plasma and Intracellular Concentrations of Bedaquiline and its M2 Metabolite in South African Patients with Drug-Resistant TB - Precious Ngwalero

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019

Pharmacokinetics and Early Bactericidal Activity of Meropenem (with Amoxicillin/Clavulanate), With and Without Rifampicin, for Drug-Susceptible TB - Ahmed Aliyu Abulfathi

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019

Co-Administration of Pretomanid with Rifampin or Rifabutin Among Patients with Pulmonary TB: Interim PK Results from “Assessing Pretomanid for Tuberculosis” (APT) Trial - Elisa Ignatius

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019

Exposures to First-Line Drugs in African and Indian Children with Drug-Susceptible Tuberculosis using Novel Fixed-Dose-Combination Tablets at WHO Dosing Recommendation in the SHINE Trial - Chishala Chabala

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019

Ethionamide Population Pharmacokinetic Model and Monte Carlo Simulation in Patients with Multidrug-Resistant Tuberculosis - Charles Peloquin

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019

Can Longitudinal PKPD Biomarkers be used to Forecast Treatment Outcome Instead of M2 Conversion? A Population Pharmacokinetic-Pharmacodynamic Analysis in Drug Sensitive Pulmonary Tuberculosis - Frank Kloprogge

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019

Pharmacokinetic-Pharmacodynamic Analysis in TB Drug Development and the Role of the WHO - Ernesto Jaramillo

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019

PK-PD of Isoniazid Given at Different Doses Among Patients with MDR-TB with INH Resistance Mediated by inhA Mutations: Modeling Results from ACTG A5312 - Kamunkhwala Gausi

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019

Population Pharmacokinetics of Linezolid in TB Patients: Dosing Regimens Simulation and Target Attainment Analysis - Charles Peloquin

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019

Drug Effect of Clofazimine on Persistent Mycobacteria Explain an Unexpected Increase of Bacterial Load in Patients - Alan Faraj

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019

Levofloxacin Target Attainment Analysis in MDR-TB Patients: Time is Ripe for Proactive TDM - Mathieu Bolhuis

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2019

Abstract: A pharmacometric framework for dose individualisation of sunitinib in GIST (#O2) | Maddalena Centanni

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018

Rationale for selecting combinations with immunotherapy | Howard Gurney, MBBS, FRACP

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018

Immunotherapy of prostate cancer and urothelial cancer. Future directions | Winald Gerritsen, MD, PhD

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018

Pharmacotherapy of Comorbities: Cancer Patients with HIV/AIDS | Michelle Rudek, PharmD, PhD

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018

Drug-Drug interactions with targeted oncolytics (in particular PPIs and TKIs) | Ron Mathijssen, MD, PhD

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018

Drug-drug interaction management with DDI-Predictor | Michel Tod, PharmD, PhD

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018

Abstract: Food intervention to make therapy with pazopanib more patient friendly and affordable (#06) | Floor Lubberman

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018

The value of surrogate endpoints in the benefit-risk assessment of new drugs | Gabe Sonke, MD, PhD

International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018